A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Myeloma Bookmark and Share

Multiple Myeloma

City of Hope is recognized internationally for its ground-breaking discoveries and clinical trials for novel new agents to treat multiple myeloma, a type of cancer that begins in plasma cells. We collaborate with other research institutions to create tomorrow’s treatments for patients at City of Hope today. We are the only Southern California member of the Multiple Myeloma Research Consortium, a collaboration of research organizations focused on rapidly bringing the most promising multiple myeloma treatments to patients.
 
Because of our vast experience in treating patients with this type of cancer, our specialists lead the field in improving outcomes for patients. City of Hope’s approach incorporates our nationally recognized stem cell transplantation program with many clinical protocols utilizing the newest agents for the treatment of myeloma.

A Commitment to Create

Designated a Comprehensive Cancer Center by the National Cancer Institute, City of Hope is acknowledged as a leader in cancer research and in transplant trials and is heavily involved in new drug trials, including a recently approved novel agent for myeloma (Carfilzomib). 
 
We offer the broadest range of therapeutic options available, including protocols developed here at City of Hope and funded in part by the National Institutes of Health. Through ongoing clinical trials, our physicians and researchers continue to lead the way in improving outcomes in myeloma patients.
 
Just as every patient is different, we recognize that every multiple myeloma case is different. What distinguishes City of Hope in the treatment of patients with blood disorders is seamless continuity of care. From a new diagnosis to treatment with the newest drugs in our clinical trials, to transplantation, patients are treated by the same team of doctors who see them through every phase of treatment and recovery. City of Hope also offers the expertise of geriatric oncologists who specialize in the treatment of older patients.
 
City of Hope is a national leader in transplant trials and heavily involved in new drug trials, including a recently approved novel agent for myeloma (Carfilzomib). City of Hope runs one of the largest and most successful hematopoietic cell transplantation (HCT) centers in the world. Since 1976, City of Hope has performed more than 11,000 transplants with excellent outcomes for patients from virtually every state and around the world.
 
Treatments vary depending on the specific type of myeloma and other factors such as the patient’s age, overall health and prior therapy. They include chemotherapy, stem cell transplantation and radiation therapy.
 
For more information on the myeloma program and treatments, click here.
 
 
 
 
 
 

Myeloma

Multiple Myeloma

City of Hope is recognized internationally for its ground-breaking discoveries and clinical trials for novel new agents to treat multiple myeloma, a type of cancer that begins in plasma cells. We collaborate with other research institutions to create tomorrow’s treatments for patients at City of Hope today. We are the only Southern California member of the Multiple Myeloma Research Consortium, a collaboration of research organizations focused on rapidly bringing the most promising multiple myeloma treatments to patients.
 
Because of our vast experience in treating patients with this type of cancer, our specialists lead the field in improving outcomes for patients. City of Hope’s approach incorporates our nationally recognized stem cell transplantation program with many clinical protocols utilizing the newest agents for the treatment of myeloma.

A Commitment to Create

Designated a Comprehensive Cancer Center by the National Cancer Institute, City of Hope is acknowledged as a leader in cancer research and in transplant trials and is heavily involved in new drug trials, including a recently approved novel agent for myeloma (Carfilzomib). 
 
We offer the broadest range of therapeutic options available, including protocols developed here at City of Hope and funded in part by the National Institutes of Health. Through ongoing clinical trials, our physicians and researchers continue to lead the way in improving outcomes in myeloma patients.
 
Just as every patient is different, we recognize that every multiple myeloma case is different. What distinguishes City of Hope in the treatment of patients with blood disorders is seamless continuity of care. From a new diagnosis to treatment with the newest drugs in our clinical trials, to transplantation, patients are treated by the same team of doctors who see them through every phase of treatment and recovery. City of Hope also offers the expertise of geriatric oncologists who specialize in the treatment of older patients.
 
City of Hope is a national leader in transplant trials and heavily involved in new drug trials, including a recently approved novel agent for myeloma (Carfilzomib). City of Hope runs one of the largest and most successful hematopoietic cell transplantation (HCT) centers in the world. Since 1976, City of Hope has performed more than 11,000 transplants with excellent outcomes for patients from virtually every state and around the world.
 
Treatments vary depending on the specific type of myeloma and other factors such as the patient’s age, overall health and prior therapy. They include chemotherapy, stem cell transplantation and radiation therapy.
 
For more information on the myeloma program and treatments, click here.
 
 
 
 
 
 
Quick Links
 
Why City of Hope
Stephen J. Forman, Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, talks about why City of Hope is a special place for cancer treatment.
 
Hematologic Cancers Support Groups
The focus of the Division of Hematopoietic Stem Cell and Leukemia Research is to improve the understanding of leukemia stem cells in order to develop cures for leukemia and other hematologic malignancies.
NEWS & UPDATES
  • Beyond the pink ribbons, special product fundraisers, and the pastel sea of color that marks October, Breast Cancer Awareness Month offers a reason to celebrate and to reflect. More than 2.8 million breast cancer survivors live in the U.S. They are survivors of the second most-common cancer in women, behind ski...
  • Gliomas, a type of tumor that grows in the brain, are very difficult to treat successfully due to their complex nature. That might not always be the case. First some background: The most aggressive and common type of primary brain tumor in adults is glioblastoma. Although the brain tumor mass can often be remov...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. The result is rashes and, sometimes, tumors, which can be mistaken for other dermatological conditions. In a smal...
  • Weighing your breast cancer risk? One study suggests a measure to consider is skirt size. A British study suggests that for each increase in skirt size every 10 years after age 25, the five-year risk of developing breast cancer postmenopause increases from one in 61 to one in 51 – a 77 percent increase in risk....
  • Runners prize medals for 5Ks and marathons. Becky Stokes has a medal she cherishes from a very different kind of race: the marathon of treatments necessary to beat her aggressive triple-negative breast cancer. Just a week ago, she completed her last radiation treatment, and danced in the hospital with the staff...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. Darakjian’s s...
  • The environment plays a role in causing cancer – this much we know. But scientists are still trying to understand what that role is, what environmental factors are in play and how precisely those factors are linked to cancer. Now City of Hope researchers have unlocked a clue as to how one carcinogen triggers ca...
  • Jonathan Yamzon, M.D., assistant clinical professor of surgery in the Division of Urology and Urologic Oncology, explains his approach to what’s known as “active surveillance” of men with prostate cancer. Patients need to be educated about their treatment options, he writes. Active surveillanc...
  • For most prostate cancer patients, surgery or radiation therapy is the initial and primary treatment against the disease. But some patients can benefit from chemotherapy and hormone therapy too, especially if there are signs of a relapse or if the cancer has spread beyond the prostate gland. Here, Cy Stein, M.D...
  • Cancer research has yielded scientific breakthroughs that offer patients more options, more hope for survival and a higher quality of life than ever before. The 14.5 million cancer patients living in the United States are living proof that cancer research saves lives. Now, in addition to the clinic, hospital an...
  • Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life. Howeve...
  • While health care reform has led to an increase in the number of people signing up for health insurance, many people remain uninsured or are not taking full advantage of the health benefits they now have. Still others are finding that, although their premiums are affordable, they aren’t able to see the do...
  • Kidney cancer rates and thyroid cancer rates in adults have continued to rise year after year. Now a new study has found that incidence rates for these cancers are also increasing in children — particularly in African-American children. The study, published online this month in Pediatrics, examined childhood ca...
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...